ClinicalTrials.gg

Program

amrubicin

Also written as “Amrubicin”, “Amrubicin Hydrochloride” and “Amrubicin (Japan only)”.

Its studies are mostly in Small Cell Lung Carcinoma · Lung Neoplasms · Breast Neoplasms, led by 3 companies.

Furthest: phase 3, since Oct 18, 20079 company-led studies, 1 open or runningNext primary completion: Oct 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb60 open or runningphase 3since Oct 18, 2007Apr 27, 2006none ahead
Sumitomo Pharma20 open or runningphase 3since Feb 1, 2006Feb 1, 2006none ahead
Gilead Sciences11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 1, 2006First study: phase 3 study in Small Cell Lung CarcinomaNew to Sumitomo PharmaSumitomo Pharma · NCT00286169 · 130 enrolled · Japan
  2. Apr 27, 2006Bristol-Myers Squibb's first study: phase 2 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00319969 · 76 enrolled · United States
  3. Sep 9, 20062 phase 2 studiesBristol-Myers Squibb · NCT00375193, NCT00380835
  4. Oct 13, 2006Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT00388960 · 99 enrolled · Belgium, Italy, Netherlands and more
  5. Oct 18, 2007Phase 3 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT00547651 · 637 enrolled · United States, Australia, Austria and more
  6. Apr 10, 2008Phase 3 study in Lung NeoplasmsSumitomo Pharma · NCT00660504 · 300 enrolled · China
  7. Jun 4, 2009Phase 1 study in Advanced Solid TumorsBristol-Myers Squibb · NCT00915083 · 24 enrolled · United States
  8. Jan 24, 2025Gilead Sciences's first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more

Ahead

  1. Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834

TargetBeta

TOP2A →read by rule
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor”ChEMBL 37, by rule

Other programs on TOP2A

ProgramCompanyFurthest phaseStudies
DoxorubicinruleHoffmann-La Rochephase 461
EtoposideruleHoffmann-La Rochephase 328
Daunorubicinrulekura-oncology-incphase 37

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more3RecruitingGilead SciencesOct 2029695
NCT00915083Advanced Solid Tumors · United States1CompletedBristol-Myers SquibbMay 1, 201124
NCT00660504Lung Neoplasms · China3CompletedSumitomo PharmaFeb 2012300
NCT00547651Small Cell Lung Carcinoma · United States, Australia, Austria and more3CompletedBristol-Myers SquibbMay 1, 2011637
NCT00388960Small Cell Lung Carcinoma · Belgium, Italy, Netherlands and more2CompletedBristol-Myers SquibbApr 1, 201099
NCT00380835Breast Neoplasms · United States2WithdrawnBristol-Myers Squibb66
NCT00375193Small Cell Lung Carcinoma · United States, Netherlands, United Kingdom2CompletedBristol-Myers SquibbMay 1, 200875
NCT00319969Small Cell Lung Carcinoma · United States2CompletedBristol-Myers SquibbJul 200876
NCT00286169Small Cell Lung Carcinoma · Japan3TerminatedSumitomo Pharma130

How it is read

Names in the registry

  • “Amrubicin”, 6 entries
  • “Amrubicin Hydrochloride”, 2 entries
  • “Amrubicin (Japan only)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.